Among which, the combinations of capmatinib with PI3K or AKT inhibitors (using GDC-0941 and MK-2206 as examples) were predicted to achieve the most substantial ORR improvement (by ∼30%) in MET-aberrant NSCLC patients, while the impact of other combinations (e.g., with MEK or ERK inhibitors, using trametinib and BVD-523 as examples) was less pronounced. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.